Outcomes for systemic therapy in women with ovarian cancer
Laurie Elit(Cameroon Baptist Convention Health Services), Lawrence Paszat(University of Toronto), Cécile Chartier(Io Therapeutics (United States)), Mark N. Levine(Juravinski Cancer Centre), Hal W. Hirte(Juravinski Cancer Centre), Amit M. Oza(Ontario Institute for Cancer Research)
Cited by 18
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k